Logo

AstraZeneca Entered into an Exclusive License Agreement with Regio Biosciences to Initiate P-IIa Trial of REG-101 for Peripheral Artery Disease

Share this
AstraZeneca Entered into an Exclusive License Agreement with Regio Biosciences to Initiate P-IIa Trial of REG-101 for Peripheral Artery Disease

AstraZeneca Entered into an Exclusive License Agreement with Regio Biosciences to Initiate P-IIa Trial of REG-101 for Peripheral Artery Disease

Shots:

  • Under the terms of an agreement, Regio gets an exclusive license for further development of REG-101 (MEDI5884) to address patients with unmet medical needs including PAD and cardiovascular disease & will lead the research, development, and commercial activities of REG-101
  • Additionally, the company is expected to initiate a P-IIa clinical program of REG-101 for the treatment of PAD in H2’22
  • REG-101 is designed to reduce the size of cholesterol-rich plaque within peripheral arteries & will directly address the pathophysiology of PAD. Regio has a partnership with CPC and multiple clinical sites in the US to conduct a P-IIa in patients with PAD

Ref: Businesswire | Image: Regio

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions